Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adults (male and female) 18 to 49 years of age at enrollment who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.~2. Negative urine pregnancy test at Visit 1 for all female subjects who are of childbearing potential.~Exclusion Criteria:~1. Male subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for at least 3 months after the last dose of investigational product.~2. Acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. Chronic medical conditions include human immunodeficiency virus, chronic hepatitis B virus (HBV) infection (HBV surface antigen positive), and/or hepatitis C virus infection.~3. History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis) to any vaccine.~4. History of microbiologically proven invasive disease caused by group B streptococcus (Streptococcus agalactiae).~5. Previous vaccination with any licensed or investigational group B streptococcus vaccine, or planned receipt during the subject's participation in the study (through the last blood draw).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Lowest dose formulation a (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Middle dose formulation a (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Highest dose formulation a (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Lowest dose formulation b (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Middle dose formulation b (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Highest dose formulation b (Type: EXPERIMENTAL): Multivalent group B streptococcus vaccine
- Placebo (Type: PLACEBO_COMPARATOR): Saline control

Based on this trial design, predict the completion outcome and termination type (if applicable).